Results 91 to 100 of about 55,815 (216)

Targeting the NR3C1‐ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer

Cancer Science, EarlyView.
The glucocorticoid receptor NR3C1 drives prostate cancer radioresistance by upregulating ACSL4. High ACSL4 levels create a lipid metabolic vulnerability. The clinical agent DHA synergizes with ACSL4 to induce lipid peroxidation and ferroptosis, effectively overcoming radioresistance.
Jing Yang, Puyuan Chen, Yawen Zheng, Feiyue Shi, Min Wang, Luwei Xu, Xiaowei Wei, Xiumei Wang   +7 more
wiley   +1 more source

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma

Advanced Science
Rapid development of resistance to sorafenib and subsequent hyperprogression in patients with advanced hepatocellular carcinoma (HCC) pose significant challenges, with the underlying mechanisms still largely unknown.
Xu‐Yan Wang, Yuan Liao, Rui‐Qi Wang, Yi‐Tong Lu, Ying‐Zhe Wang, Yu‐Qi Xin, Dong‐Ming Kuang, Xiang‐Ming Lao, Junying Xu, Zhi‐Ling Zhou, Kunhua Hu   +10 more
doaj   +1 more source

Targeting m6A Modifications Regulating Ferroptosis Offers Novel Therapy in Diseases

Cell Proliferation, EarlyView.
m6A RNA modification regulates ferroptosis by balancing iron metabolism, lipid peroxidation, and antioxidant defenses. Dysregulated m6A signaling disrupts pro‐ and anti‐ferroptotic factors, leading to excess ROS, Fe3+ accumulation, and lipid peroxidation–driven cell death. Targeting m6A‐mediated ferroptotic regulation represents a promising therapeutic
Lida Du, Joshua S. Fleishman, Shuang Wu, Yuan Zhou, Clara X. Wang, Haitong Wang, Yumin Wang, Hongquan Wang   +7 more
wiley   +1 more source

Biliary Abnormality on Imaging During Lenvatinib Plus Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma: A Pilot Descriptive Study

Hepatology Research, EarlyView.
ABSTRACT Aim To evaluate the frequency, imaging characteristics, associated factors, and clinical significance of biliary abnormalities on imaging in patients receiving lenvatinib (LEN) plus cisplatin hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma (HCC).
Hirohito Osanai, Kazuto Kozaka, Takashi Matsubara, Norihide Yoneda, Takahiro Ogi, Kenichiro Okumura, Atsushi Takamatsu, Azusa Kitao, Shintaro Yagi, Taro Yamashita, Satoshi Kobayashi   +10 more
wiley   +1 more source

Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma: A Case Report

Gut and Liver, 2010
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe.
doaj   +1 more source

Potential Role of Liver Transplantation for Child–Pugh Class A Hepatocellular Carcinoma: Prognosis and Medical Expenditure in Japan—A Retrospective Single‐Center Study

Hepatology Research, EarlyView.
Among patients with CP‐A HCC initially within the Japan criteria, some lose oncological eligibility for LT before hepatic decompensation. Further studies are needed to identify baseline factors associated with poor outcomes and to evaluate their relevance to future LT candidacy.
Akihiro Seki, Tomoyoshi Chiba, Shintaro Yagi, Rika Horii, Noboru Takata, Hiroki Nomura, Masaki Miyazawa, Tomoyuki Hayashi, Takeshi Terashima, Shinichi Nakanuma, Mitsuyoshi Okazaki, Satoshi Takada, Tatsuya Yamashita, Masao Honda, Hajime Takatori, Tetsuro Shimakami, Taro Yamashita   +16 more
wiley   +1 more source

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

Experimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves, Rheure Alves‐Lopes, Augusto C. Montezano, Rhian M. Touyz   +3 more
wiley   +1 more source

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management

American Journal of Hematology, Volume 101, Issue 9, Page 2393-2411, September 2026.
ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley   +1 more source

Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration‐resistant disease. Therapy‐induced neuroendocrine prostate cancer (t‐NEPC) is an aggressive variant with limited treatment options. Case Presentation A 72‐year‐old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen ...
Toshiaki Kayaba, Satoshi Washino, Takanori Hayase, Kai Yazaki, Kimitoshi Saito, Tomoaki Miyagawa   +5 more
wiley   +1 more source

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K, Pritam Kumar Roy, Maniklal Shee, Budhaditya Mukherjee, Aoife Ward Gahlawat, Mahitosh Mandal   +5 more
wiley   +1 more source